Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
MM-151 is a combination of three human monoclonal antibodies targeting distinct, non-overlapping epitopes of epidermal growth factor receptor (EGFR), thereby preventing the binding of ligands and inhibiting EGFR-ERK-mediated signaling (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MM-151||EGFR Antibody 29||MM-151 is a combination of three human monoclonal antibodies targeting distinct, non-overlapping epitopes of epidermal growth factor receptor (EGFR), thereby preventing the binding of ligands and inhibiting EGFR-ERK-mediated signaling (PMID: 26843189).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||MM-151||Clinical Study||Actionable||In a Phase I trial, MM-151 treatment resulted in partial response in 17% (5/29) and stable disease in 28% (8/29) of colorectal patients (J Clin Oncol 34, 2016 (suppl; abstr 2518)).||detail...|
|Unknown unknown||Advanced Solid Tumor||not applicable||MM-151||Phase I||Actionable||In a Phase I trial, MM-151 displayed safety in preliminary efficacy in a variety of advanced solid tumors (J Clin Oncol 33, 2015 (suppl 3; abstr 647)).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02538627||Phase I||Seribantumab MM-151||Phase 1 Combination Study of MM-151 and MM-121||Terminated|
|NCT01520389||Phase I||MM-151 Irinotecan||Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment||Completed|